Modified TGF-beta oligonucleotides

A method of inhibiting and/or treating a malignant and/or a benign tumor, fibrosis, cirrhosis, scleroderma or a related dermatologic disease, or a CNS disease comprising administering an oligonucleotide to a subject in need thereof, wherein one or more nucleotide(s) of the oligonucleotide is/are LNA modified nucleotides, wherein the modified nucleotide is a LNA, and/or an ENA, polyalkylene oxide-, 2′-fluoro-, 2′-O-methoxy-, and/or 2′O-methyl-modified nucleotide;

• wherein said oligonucleotide is GTCTTGCAGGTGGA (SEQ. ID. NO. 252), wherein nucleotides in bold letters are LNA, and wherein the malignant and/or benign tumor, fibrosis, cirrhosis, scleroderma or related dermatologic disease, or CNS disease is at least one of solid tumors, blood born tumors, leukemia, tumor metastasis, hemangiomas, acoustic neuromas, neurofibromas, trachomas, pyogenic granulomas, psoriasis, astrocytoma, acoustic neuroma, blastoma, Ewing's tumor, craniopharyngioma, ependymoma, medulloblastoma, glioma, hemangioblastoma, Hodgkins-lymphoma, leukaemia, mesothelioma, neuroblastoma, neurofibroma, non-Hodgkins lymphoma, pinealoma, retinoblastoma, sarcoma, seminoma, trachomas, Wilm's tumor, bile duct carcinoma, bladder carcinoma, brain tumor, breast cancer, bronchogenic carcinoma, carcinoma of the kidney, cervical cancer, choriocarcinoma, choroidcarcinoma, cystadenocarcinoma, embryonal carcinoma, epithelial carcinoma, esophageal cancer, cervical carcinoma, colon carcinoma, colorectal carcinoma, endometrial cancer, gallbladder cancer, gastric cancer, liver carcinoma, lung carcinoma, medullary carcinoma, neck cancer, non-small-cell bronchogenic/lung carcinoma, ovarian cancer, pancreas carcinoma, papillary carcinoma, papillary adenocarcinoma, prostate cancer, small intestine carcinoma, prostate carcinoma, rectal cancer, renal cell carcinoma, skin cancer, small-cell bronchogenic/lung carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, testicular carcinoma, or uterine cancer.